Stifel Starts FibroGen (FGEN) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Stifel Starts FibroGen (FGEN) at Buy
December 9, 2014 7:39 AM EST
(Updated - December 9, 2014 9:55 AM EST)
RBC Capital initiated coverage on FibroGen (NASDAQ: FGEN) with an Outperform rating and a price target of $38.00.
Analyst Michael J. Yee said, "We believe FGEN represents a compelling long-term opportunity with two multi-billion-dollar programs: 1) Novel Phase III anemia program with... More
December 9, 2014 7:38 AM EST
Goldman Sachs initiates coverage on FibroGen (NASDAQ: FGEN) with a Buy rating and a price target of $32.00.
Analyst Terence Flynn said, "Based on the Roxa Phase 2 data we see three potential benefits over injectable ESAs potential to improve safety (focus will be on... More
December 8, 2014 7:42 AM EST
William Blair initiated coverage on FibroGen (NASDAQ: FGEN) with an Outperform rating.
Analyst John Sonnier estimated that the company would generate revenue of $136 million in 2014 and $191 million in 2015, and believes the company has sufficient capital to sustain itself for at least two years.
"Our bullish investment outlook on FibroGen is based on a variety of factors," Sonnier said. "These include the strength of lead product candidates roxadustat, which is... More
